 |
15 Diseases |  |
0 Trials |
|
0 Trials |  |
26 News |  |
- | rHIgM22 / Acorda
Journal: Comparison of Hemopoietic Biochemical Parameters in the First, Second, and Third Trimester of Pregnant Females Attending a Tertiary Care Hospital of Western Rajasthan. (Pubmed Central) - May 8, 2024
- | rHIgM22 / Acorda
Journal, Machine learning: ASPTF: A computational tool to predict abiotic stress-responsive transcription factors in plants by employing machine learning algorithms. (Pubmed Central) - Apr 25, 2024
To facilitate the adoption of the proposed strategy by users, the technique was implemented and made available as a prediction server called ASPTF, accessible at https://iasri-sg.icar.gov.in/asptf/. The developed approach and the corresponding web application are anticipated to complement experimental methods in the identification of transcription factors (TFs) responsive to abiotic stress in plants.
- | rHIgM22 / Acorda
Journal: Identification of the Lipid Antigens Recognized by rHIgM22, a Remyelination-Promoting Antibody. (Pubmed Central) - Jan 26, 2023
Remarkably, binding of rHIgM22 to sulfatide in lipid monolayers can be positively or negatively regulated by the presence of other lipids. Moreover, rHIgM22 also binds to phosphatidylinositol, phosphatidylserine and phosphatidic acid, suggesting that not only sulfatide, but also other membrane lipids might play a role in the binding of rHIgM22 to oligodendrocytes and to other cell types not expressing sulfatide.
- rHIgM22 / Acorda
Dose to the Bladder Trigone and Acute Urinary Toxicity after Prostate SBRT in a Randomized Phase 3 Trial (Henry B. Gonzalez Convention Center, Exhibit Hall 1) - Aug 1, 2022 - Abstract #ASTRO2022ASTRO_1578;
P=N/A
There is also a trend in the association of maximal dose to the bladder trigone with patient-reported outcomes, suggesting that attention should be paid to this subvolume. Further investigation in larger studies on the dosimetric impact to urinary tract subvolumes in prostate SBRT is warranted.
- | rHIgM22 / Acorda
Journal: A double-blind, placebo-controlled, single-ascending-dose intravenous infusion study of rHIgM22 in subjects with multiple sclerosis immediately following a relapse. (Pubmed Central) - May 3, 2022
P1
This study demonstrated safety of an antibody directed to myelin and oligodendrocytes in the course of active demyelinating disease. Further research into rHIgM22 is warranted.ClinicalTrials.gov: NCT02398461 https://clinicaltrials.gov/ct2/show/study/NCT02398461?term=M22&draw=2&rank=8.
- | rHIgM22 / Acorda
Trial completion: An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse (clinicaltrials.gov) - Dec 2, 2017
P1, N=27, Completed, Sponsor: Acorda Therapeutics
Further research into rHIgM22 is warranted.ClinicalTrials.gov: NCT02398461 https://clinicaltrials.gov/ct2/show/study/NCT02398461?term=M22&draw=2&rank=8. Active, not recruiting --> Completed
- rHIgM22 / Acorda
Enrollment closed, Trial primary completion date: An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse (clinicaltrials.gov) - May 12, 2017
P1, N=30, Active, not recruiting, Sponsor: Acorda Therapeutics
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Sep 2017
- rHIgM22 / Acorda
Trial primary completion date: An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse (clinicaltrials.gov) - Oct 18, 2016
P1, N=30, Recruiting, Sponsor: Acorda Therapeutics
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2017 --> Sep 2017 Trial primary completion date: Sep 2016 --> Jun 2017
- rHIgM22 / Acorda
Enrollment open: An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse (clinicaltrials.gov) - Jun 15, 2015
P1, N=30, Recruiting, Sponsor: Acorda Therapeutics
Trial primary completion date: Sep 2016 --> Jun 2017 Not yet recruiting --> Recruiting
- | rHIgM22 / Acorda
Trial completion, Enrollment change, Trial primary completion date: The Effect of Protein Quality and Time-factor by Consumption of a Pre-meal on Postprandial Lipemia in Subjects With the Metabolic Syndrome. (clinicaltrials.gov) - May 5, 2015
P=N/A, N=16, Completed, Sponsor: Aarhus University Hospital
Not yet recruiting --> Recruiting Recruiting --> Completed | N=20 --> 16 | Trial primary completion date: Dec 2014 --> Mar 2015
- | rHIgM22 / Acorda
New P1 trial: An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis Immediately Following a Relapse (clinicaltrials.gov) - Mar 25, 2015
P1, N=30, Not yet recruiting, Sponsor: Acorda Therapeutics
- ||| rHIgM22 / Acorda
Trial completion: An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis (clinicaltrials.gov) - Feb 11, 2015
P1, N=72, Completed, Sponsor: Acorda Therapeutics
Recruiting --> Completed | N=20 --> 16 | Trial primary completion date: Dec 2014 --> Mar 2015 Active, not recruiting --> Completed
- rHIgM22 / Acorda
Clinical: The Effect of Protein Quality and Time-factor by Consumption of a Pre-meal on Postprandial Lipemia in Subjects With the Metabolic Syndrome. (clinicaltrials.gov) - Aug 29, 2014
P=N/A, N=20, Recruiting, Sponsor: Aarhus University Hospital
- || rHIgM22 / Acorda
Trial primary completion date: An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis (clinicaltrials.gov) - May 29, 2014
P1, N=71, Active, not recruiting, Sponsor: Acorda Therapeutics
Active, not recruiting --> Completed Trial primary completion date: Jul 2014 --> Nov 2014
- || rHIgM22 / Acorda
Enrollment closed: An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis (clinicaltrials.gov) - May 29, 2014
P1, N=71, Active, not recruiting, Sponsor: Acorda Therapeutics
Trial primary completion date: Jul 2014 --> Nov 2014 Recruiting --> Active, not recruiting
- ||| rHIgM22 / Acorda
Enrollment open: An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis (clinicaltrials.gov) - Apr 2, 2013
P1, N=71, Recruiting, Sponsor: Acorda Therapeutics
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| rHIgM22 / Acorda
New P1 trial: An Intravenous Infusion Study of rHIgM22 in Patients With Multiple Sclerosis (clinicaltrials.gov) - Feb 28, 2013
P1, N=71, Recruiting, Sponsor: Acorda Therapeutics